UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE
ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 11, 2013
________________
NOVO
NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo
Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 11 November 2013 – On 31 October 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.
Under the programme initiated 31 October 2013, Novo Nordisk will repurchase B shares for an amount of DKK 2.8 billion in the period from 31 October 2013 to 28 January 2014. In addition, Novo Nordisk expects to purchase B-shares from employees in November 2013 for approximately DKK 0.2 billion. The repurchase of shares in this transaction is not part of the Safe Harbour programme, but is part of the overall DKK 14.0 billion share repurchase programme.
Since the announcement as of 31 October 2013, the following transactions have been made under the programme:
| Number of | Average | Transaction | |
| shares | purchase price | value, DKK | |
| Accumulated, last announcement | 0 | 0 | |
| 31 October 2013 | 37,500 | 927.04 | 34,763,955 |
| 1 November 2013 | 55,000 | 921.01 | 50,655,512 |
| 4 November 2013 | 50,000 | 922.42 | 46,121,170 |
| 5 November 2013 | 48,000 | 918.23 | 44,075,093 |
| 6 November 2013 | 45,000 | 932.41 | 41,958,518 |
| 7 November 2013 | 47,000 | 946.37 | 44,479,155 |
| 8 November 2013 | 45,000 | 939.65 | 42,284,381 |
| Accumulated under the programme | 327,500 | 304,337,782 |
| Novo Nordisk A/S | Novo Allé | Telephone: | CVR no: | |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | 24 25 67 90 | |
| Denmark | Internet: | |||
| www.novonordisk.com | ||||
| Company announcement No 70 / 2013 | ||||
Page 2 of 2
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 346,274 B shares in the period from 31 October 2013 to 8 November 2013. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 18,862,144 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 8 November 2013, Novo Nordisk has repurchased a total of 11,765,943 B shares equal to a transaction value of DKK 11,304,336,453.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
| Further information | ||
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
| Novo Nordisk A/S | Novo Allé | Telephone: | CVR no: | |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | 24 25 67 90 | |
| Denmark | Internet: | |||
| www.novonordisk.com | ||||
| Company announcement No 70 / 2013 | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 11, 2013 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |